LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
the launch of the CONSTRUX® Mini PEEK Titanium Composite™
(PTC) Spacer System through its spine distribution network. This
anterior cervical interbody system incorporates a unique technology that
combines the benefits of PEEK's imaging capabilities with the potential
of bone ingrowth from porous titanium endplates.
Dr. Scott Stanley, Medical Director of the Spine Program at Parker
Adventist Hospital in Parker, Colorado, who is the primary surgeon
innovator behind the technology stated, "After years of hard work in
this product's development, I am thrilled to utilize this implant for my
patients. I believe that the porous interface will allow for potential
bone ingrowth as demonstrated in the orthopedic joint arthroplasty
literature. This product will allow patients to return to
extracurricular activities and activities of daily living in a timely
fashion."
The CONSTRUX® Mini PEEK Titanium Composite™ (PTC)
Spacer System has porous titanium endplates that provide a 3D porous
material with the potential for bone ingrowth that may create a bond
between the bone and the implant. The implant also features a PEEK core,
which allows for post and intraoperative imaging without the severe
image distortion associated with metal designs currently on the market.
"We are very excited about the launch of this novel, differentiated
cervical interbody system. It represents the beginning of a series of
product launches in 2013 that will bring our cervical implant product
offering to the forefront of the industry," said President and Chief
Executive Officer Robert Vaters.
This PEEK/ Titanium hybrid offers three footprints and various heights
to address the cervical interbody fusion solution. These implants work
with the CONSTRUX Mini PEEK Spacer System instrument trays currently in
the field.
About Orthofix:
Orthofix International N.V. is a diversified, global medical device
company focused on developing and delivering innovative repair and
regenerative solutions to the spine and orthopedic markets. Orthofix's
products are widely distributed around the world to surgeons and
patients via Orthofix's sales representatives and its subsidiaries, and
via collaborations with other leading orthopedic product companies. In
addition, Orthofix is collaborating on R&D activities with leading
research and clinical organizations such as the Musculoskeletal
Transplant Foundation, the Orthopedic Research and Education Foundation,
and Texas Scottish Rite Hospital for Children. For more information
about Orthofix, please visit www.orthofix.com.
Orthofix
Mark Quick, 214-937-2924
Director of Investor
Relations and Business Development
markquick@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media